Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel.

Zhang W, Zhang D, Tan J, Cong H.

J Nanosci Nanotechnol. 2012 Sep;12(9):7211-4.

PMID:
23035454
2.

[Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].

Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW.

Ai Zheng. 2006 Apr;25(4):398-403. Chinese.

PMID:
16613669
3.

S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.

He Z, Gao J, Wang Q, Liu M, Li Y, Li X, Tang H, Zheng J.

Oncol Rep. 2008 Aug;20(2):325-32.

PMID:
18636193
4.

Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.

Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R.

Oncology. 2004;66(1):53-61.

PMID:
15031599
5.

[Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].

Yan XJ, Liang LZ, Zeng ZY, Fu LW, Shi Z.

Zhonghua Fu Chan Ke Za Zhi. 2005 Sep;40(9):609-13. Chinese.

PMID:
16202317
6.
7.

Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.

Ho EA, Soo PL, Allen C, Piquette-Miller M.

J Control Release. 2007 Jan 22;117(1):20-7. Epub 2006 Oct 7.

PMID:
17113177
8.

Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.

Gao JH, He ZJ, Wang Q, Li X, Li YX, Liu M, Zheng JH, Tang H.

Chin Med J (Engl). 2008 Aug 20;121(16):1563-8.

PMID:
18982869
9.

BAD partly reverses paclitaxel resistance in human ovarian cancer cells.

Strobel T, Tai YT, Korsmeyer S, Cannistra SA.

Oncogene. 1998 Nov 12;17(19):2419-27.

10.

Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.

Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V.

Biochem J. 2006 Apr 15;395(2):311-8.

11.

iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.

Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN.

Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.

12.

Paclitaxel-induced apoptosis in human ovarian cancer cell line COC1.

Wang S, Lu Y, Ma D.

J Tongji Med Univ. 1999;19(2):124-6.

PMID:
12840855
14.

Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.

Li J, Liu P, Mao H, Wanga A, Zhang X.

Oncol Rep. 2009 Jun;21(6):1605-10.

PMID:
19424643
15.

Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.

Kim SH, Juhnn YS, Song YS.

Ann N Y Acad Sci. 2007 Jan;1095:82-9.

PMID:
17404021
16.

Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.

Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van Nagell JR, Zimmer SG.

Anticancer Res. 2004 Mar-Apr;24(2B):539-45.

17.

Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.

Munkarah AR, Genhai Z, Morris R, Baker VV, Deppe G, Diamond MP, Saed GM.

Gynecol Oncol. 2003 Mar;88(3):429-33.

PMID:
12648598
18.

Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells.

Jeansonne DP, Koh GY, Zhang F, Kirk-Ballard H, Wolff L, Liu D, Eilertsen K, Liu Z.

Oncol Rep. 2011 May;25(5):1473-80. doi: 10.3892/or.2011.1187. Epub 2011 Feb 17.

PMID:
21331447
19.

Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.

Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J.

Endocr Relat Cancer. 2010 Jan 29;17(1):39-50. doi: 10.1677/ERC-08-0296. Print 2010 Mar.

20.

[Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor].

Wang YZ, Fang XL, Li YJ, Zhang ZW, Han LM, Sha XY.

Yao Xue Xue Bao. 2008 Jun;43(6):640-6. Chinese.

PMID:
18822969

Supplemental Content

Support Center